NCI‐H460 (KRAS/LKB1 mutant) cells were selected as NSCLC cells showing the highest rate of BRD2‐FTH1 co‐localization and resistance to JQ1 [37, 41, 47]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.